Genomic and non-genomic effects of glucocorticoids
- Authors: Todosenko N.M1, Koroleva Y.A1, Khaziakhmatova O.G1, Yurova K.A1, Litvinova L.S1
-
Affiliations:
- Immanuel Kant Baltic Federal University
- Issue: Vol 12, No 1 (2017)
- Pages: 27-33
- Section: Articles
- Submitted: 05.01.2023
- Published: 15.03.2017
- URL: https://genescells.ru/2313-1829/article/view/120636
- DOI: https://doi.org/10.23868/gc120636
- ID: 120636
Cite item
Abstract
Keywords
Full Text
About the authors
N. M Todosenko
Immanuel Kant Baltic Federal UniversityKaliningrad, Russia
Yu. A Koroleva
Immanuel Kant Baltic Federal UniversityKaliningrad, Russia
O. G Khaziakhmatova
Immanuel Kant Baltic Federal UniversityKaliningrad, Russia
K. A Yurova
Immanuel Kant Baltic Federal UniversityKaliningrad, Russia
L. S Litvinova
Immanuel Kant Baltic Federal UniversityKaliningrad, Russia
References
- Jiang Ch.L., Liu L., Li Zh. et al. The novel strategy of glucocorticoid drug development via targeting nongenomic mechanisms. Steroids 2015; 102: 27-31.
- Adcock I.M., Caramori G. Cross-talk between pro-inflammatory transcription factors and glucocorticoids. Immunology and Cell Biology 2001; 79(4): 376-84.
- Garcia-Magallon B., Silva-Fernandez L., Andreu-Sanchez J.L. et al. Update on the Use of Steroids in Rheumatoid Arthritis. Reumatol. Clin. 2013; 9(5): 297-302.
- Saleh K.J., Kurdi A.J., El-Othmani M.M. et al. Perioperative Treatment of Patients with Rheumatoid Arthritis. J. Am. Acad. Orthop. Surg. 2015; 23(9): 38-48.
- Zampeli E., Vlachoyiannopoulos P.G., Tzioufas A.G. Treatment of rheumatoid arthritis: Unraveling the conundrum. Journal of Autoimmunity 2015; 65: 1-18.
- Black R.J., Joseph R.M., Brown B. et al. Half of UK patients with rheumatoid arthritis are prescribed oral glucocorticoid therapy in primary care: a retrospective drug utilisation study. Arthritis Research & Therapy 2015; 17: 375.
- Oppong E., Cato A.C.B. Effects of Glucocorticoids in the Immune System. In: Wang J.C., Harris Ch., editors. Glucocorticoid signaling from molecules to mice to man. Advances in Experimental Medicine and Biology. New York: Springer; 2015. p. 217-33.
- John K., Marino J.S., Sanchez E.R. et al. The glucocorticoid receptor: cause of or cure for obesity? Am. J. Physiol. Endocrinol. Metab. 2016; 310(4): 249-57.
- Cruz-Topete D., Cidlowski J.A. One hormone, two actions: anti- and pro-Inflammatory effects of glucocorticoids. Neuroimmunomodulation 2015; 22(1-2): 20-32.
- Baschant U., Tuckermann J. The role of the glucocorticoid receptor in inflammation and immunity. Journal of Steroid Biochemistry & Molecular Biology 2010; 120(2-3): 69-75.
- Revollo J.R., Cidlowski J.A. Mechanisms generating diversity in glucocorticoid receptor signaling. Glucocorticoids and Mood: Ann. N.Y. Acad. Sci. 2009; 1179: 167-78.
- Ratman D., Berghe W.V., Dejager L. et al. How glucocorticoid receptors modulate the activity of other transcription factors: A scope beyond tethering. Molecular and Cellular Endocrinology 2013; 380(1-2): 41-54.
- Bazso A., Szappanos A., Patocs A. et al. The importance of glucocorticoid receptors in systemic lupus erythaematosus. A systematic review. Autoimmun. Rev. 2015; 14(4): 349-51.
- Ayroldi E., Macchiarulo A., Riccardi C. Targeting glucocorticoid side effects: selective glucocorticoid receptor modulator or glucocorticoidinduced leucine zipper? A perspective. Faseb J. 201 4; 28(12): 5055-70.
- Hartmann K., Koenen M., Schauer S. et al. Molecular Actions of Glucocorticoids in Cartilage and Bone During Health, Disease, and Steroid Therapy. Physiol. Rev. 2016; 96(2): 409-47.
- Silverman M.N., Sternberg E.M. Glucocorticoid regulation of inflammation and its functional correlates: from HPA axis to glucocorticoid receptor dysfunction. Ann. N.Y. Acad. Sci. 2012; 1261: 55-63.
- Ingawale D.K., Mandlik S.K., Patel S.S. An emphasis on molecular mechanisms of anti-inflammatory effects and glucocorticoid resistance. J. Complement Integr. Med. 2015; 12(1): 1-13.
- Bamberger C.M., Bamberger A.M., de Castro M. et al. Glucocorticoid receptor beta, a potential endogenous inhibitor of glucocorticoid action in humans. J. Clin. Invest. 1995; 95(6): 2435-41.
- Nicolaides N.C., Galata Z., Kino T. et al. The human glucocorticoid receptor: molecular basis of biologic function. Steroids 2010; 75(1): 1-12.
- Oakley R.H., Sar M., Cidlowski J.A. The human glucocorticoid receptor beta isoform. Expression, biochemical properties, and putative function. J. Biol. Chem. 1996; 271(16): 9550-9.
- Ray D.W., Davis J.R., White A. et al. Glucocorticoid receptor structure and function in glucocorticoid-resistant small cell lung carcinoma cells. Cancer Res. 1996; 56(14): 3276-80.
- Kelly A., Bowen H., Jee Y.K. et al. The glucocorticoid receptor beta isoform can mediate transcriptional repression by recruiting histone deacetylases. J. Allergy Clin. Immunol. 2008; 121(1): 203-8.
- Kim S.H., Kim D.H., Lavender P. et al. Repression of TNF -а-induced IL-8 expression by the glucocorticoid receptor involves inhibition of histone H4 acetylation. Exp. Mol. Med. 2009; 41(5): 297-306.
- Li L.B., Leung D.Y.M., Martin R.J. et al. Inhibition of histone deacetylase 2 expression by elevated glucocorticoid receptor in steroid-resistant asthma. Am. J. Respir. Crit. Care Med. 2010; 182(7): 877-83.
- Lui J.C., Nilsson O., Baron J. Growth plate senescence and catch-up growth. Endocr. Dev. 2011; 21: 23-9.
- Grad I., Picard D. The glucocorticoid responses are shaped by molecular chaperones. Mol. Cell Endocrinol. 2007; 275(1-2): 2-12.
- Pratt W.B. The role of heat shock proteins in regulating the function, folding, and trafficking of the glucocorticoid receptor. J. Biol. Chem. 1993; 268(29): 21455-8.
- Pratt W.B., Toft D.O. Regulation of signaling protein function and trafficking by the hsp90/hsp70-based chaperone machinery. Exp. Biol. Med. 2003; 228(2): 111-33.
- Pratt W.B., Toft D.O. Steroid receptor interactions with heat shock protein and immunophilin chaperones. Endocr. Rev. 1997; 18(3): 306-60.
- Riggs D.L., Roberts P.J., Chirillo S.C. et al. The Hsp90-binding peptidylprolyl isomerase FKBP52 potentiates glucocorticoid signaling in vivo. EMBO J. 2003; 22(5): 1158-67.
- Vermeer H., Hendriks-Stegeman B.I., van der Burg B. et al. Glucocorticoid-induced increase in lymphocytic FKBP51 messenger ribonucleic acid expression: a potential marker for glucocorticoid sensitivity, potency, and bioavailability. J. Clin. Endocrinol. Metab. 2003; 88(1): 277-84.